脊柱关节炎外周关节炎疾病活动度评估工具测量性能的系统文献综述
该系统文献综述旨在总结和比较用于评估中轴型脊柱关节炎(axSpA)和外周型脊柱关节炎(pSpA)外周关节炎疾病活动度的工具的测量性能。共筛选4364条记录,纳入8项研究,发现axSpA证据有限且多为AMBER,pSpA复合工具表现较好(多为GREEN),但缺乏重测信度和意义阈值的研究。
要点
- axSpA外周关节炎评估工具证据有限,PGA、CRP和BASDAI多为AMBER。
- pSpA复合工具(BASDAI、ASDAS、DAPSA)表现较好,多为GREEN。
- 所有工具均缺乏重测信度和意义阈值的研究证据。
核心结论
- 支持脊柱关节炎外周关节炎评估工具的证据仍然稀缺,尤其在axSpA中。
- pSpA中复合工具表现更好,但证据缺口持续存在,需要验证性、领域特异性工具。
研究设计与样本
- 系统文献综述,检索Medline/EMBASE/Cochrane至2025年2月,遵循Population-Instrument-Measurement框架。
- 纳入成人axSpA或pSpA伴外周关节炎的研究,评估构建效度和区分度,使用OMERACT良好方法清单评估偏倚风险并按OMERACT规则合成证据。
- 共筛选4364条记录,纳入8项研究。
主要发现
- axSpA证据仅限于PGA、CRP和BASDAI,构建效度、纵向构建效度和临床试验区分度多为AMBER。
- pSpA中复合工具表现更好,BASDAI、ASDAS和DAPSA多为GREEN。
- 无研究提供重测信度或意义阈值。
关键数值与推荐
- 证据分级采用OMERACT规则:GREEN为良好,AMBER为足够,RED为表现差。
- 评估的测量性能包括构建效度(相关性假设;已知组区分)和区分度(重测信度、反应性;临床试验区分度;意义阈值)。
临床怎么用
- 在pSpA中可优先考虑BASDAI、ASDAS和DAPSA评估外周关节炎疾病活动度。
- 在axSpA中外周关节炎评估工具证据有限,选择需谨慎。
局限性
- 纳入研究数量少(仅8项),证据基础薄弱。
- 缺乏重测信度和意义阈值的研究。
- axSpA中外周关节炎评估工具的证据尤其有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Assessment of SpondyloArthritis International Society-Spondyloarthritis and Peripheral Arthritis Disease Activity Instrument Selection and Evaluation (ASAS-SPARADISE) project aims to identify instruments to assess disease activity due to peripheral arthritis in axial (axSpA) and peripheral spondyloarthritis (pSpA). We aimed to summarise and compare the measurement properties of instruments used for this purpose as part of the ASAS-SPARADISE. METHODS: A systematic literature review (Medline/EMBASE/Cochrane; until February 2025) was conducted following the Population-Instrument-Measurement framework. Eligible studies included adults with axSpA or pSpA and peripheral arthritis. Instruments retained from a previous review, after domain-match and feasibility assessment, included: Patient Global Assessment (PGA), swollen joint count (66/44), tender joint count (68/44), C reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score (ASDAS), Disease Activity Index for Psoriatic Arthritis (DAPSA) and Disease Activity Score using 44 joints. Measurement properties evaluated were construct validity (correlation hypotheses; known-groups discrimination) and discrimination (test-retest reliability, responsiveness; clinical trial discrimination; thresholds of meaning). Risk of bias was assessed using the Outcome Measures on Rheumatology (OMERACT) Good Methods Checklist and evidence was synthesised following OMERACT rules (GREEN-good; AMBER-adequate; RED-poor performance). RESULTS: Of 4,364 records screened, eight studies were eligible. Evidence in axSpA was limited to PGA, CRP and BASDAI, rating mostly AMBER for construct validity, longitudinal construct validity and discrimination in clinical trials. In pSpA, composite instruments showed better results, with BASDAI, ASDAS and DAPSA rating mostly GREEN. No study provided test-retest reliability or thresholds of meaning. CONCLUSIONS: Evidence supporting instruments to assess peripheral arthritis in spondyloarthritis remains scarce, especially in axSpA. Composite instruments in pSpA performed better, but evidence gaps persist, highlighting the need for validated, domain-specific instruments. PROSPERO REGISTRATION NUMBER: CRD420251177596.
引用
- Capelusnik D, López-Medina C, Weber C, et al. Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review. RMD Open. 2026. PMID: 42373103. doi:10.1136/rmdopen-2026-006900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。